Zhonghua yi xue za zhi · 2010
[Experimental study of protective effects of hepatotrophic factors on hepatic functions in rats with portal hypertension after portacaval shunt].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jiang Peng, Zhao Jing-Ming, Zhang Zhong-Tao
Аннотация
OBJECTIVE: To investigate the protective effects of hepatotrophic factors (hepatocyte growth-promoting factor and insulin) on hepatic functions and pathology in rats with portal hypertension after portacaval shunt.
METHODS: The rats of hepatic cirrhosis with portal hypertension were randomly assigned into 1 control group, 1 model group and 4 treatment groups (NS, HGF, INS, HGF + INS). An end-side portacaval shunt was performed in the treatment group. The hepatotrophic factors were respectively injected into portal vein. After treatment, the serum levels of ALT (alanine aminotransferase), AST (aspartate aminotransferase), HA (hyaluronic acid) and LN (laminin) were determined by radioimmunoassay. And then according to the hematoxylin and eosin (H&E) staining results, the tissue slides were prepared.
RESULTS: The serum levels of ALT (30.13 ± 4.12 U/L), AST (133.75 ± 21.18 U/L), HA (322.49 ± 52.33 µg/L) and LN (23.89 ± 5.03 µg/L) were lower in the HGF + INS group than those in the NS group (all P < 0.01); the scores of hepatic fibrosis stages (1.63 ± 0.74) and collagen semiquantitative of Masson stain (10.17 ± 1.14 × 10(-2)) were significantly reduced in the HGF + INS group than those in the NS group (all P < 0.01).
CONCLUSION: The injection of hepatotrophic factors through portal vein after portacaval shunt can improve hepatic functions, reduce the damages of hepatocyte and improve the degree of hepatic fibrosis.
METHODS: The rats of hepatic cirrhosis with portal hypertension were randomly assigned into 1 control group, 1 model group and 4 treatment groups (NS, HGF, INS, HGF + INS). An end-side portacaval shunt was performed in the treatment group. The hepatotrophic factors were respectively injected into portal vein. After treatment, the serum levels of ALT (alanine aminotransferase), AST (aspartate aminotransferase), HA (hyaluronic acid) and LN (laminin) were determined by radioimmunoassay. And then according to the hematoxylin and eosin (H&E) staining results, the tissue slides were prepared.
RESULTS: The serum levels of ALT (30.13 ± 4.12 U/L), AST (133.75 ± 21.18 U/L), HA (322.49 ± 52.33 µg/L) and LN (23.89 ± 5.03 µg/L) were lower in the HGF + INS group than those in the NS group (all P < 0.01); the scores of hepatic fibrosis stages (1.63 ± 0.74) and collagen semiquantitative of Masson stain (10.17 ± 1.14 × 10(-2)) were significantly reduced in the HGF + INS group than those in the NS group (all P < 0.01).
CONCLUSION: The injection of hepatotrophic factors through portal vein after portacaval shunt can improve hepatic functions, reduce the damages of hepatocyte and improve the degree of hepatic fibrosis.